European Commission Grants Approval for KALYDECO® to Treat Cystic Fibrosis in Infants as Young as 1 Month Old, Announces Vertex

Vertex Pharmaceuticals (Nasdaq: VRTX) has received approval from the European Commission for the expansion of KALYDECO® (ivacaftor) labeling. This approval allows for the treatment of infants as young as 1…

Read MoreEuropean Commission Grants Approval for KALYDECO® to Treat Cystic Fibrosis in Infants as Young as 1 Month Old, Announces Vertex